No headlines found.
ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call
Globe Newswire (Tue, 23-Apr 8:30 AM ET)
ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum
Globe Newswire (Wed, 13-Mar 8:30 AM ET)
ICU Medical to Present at the Raymond James 45?? Annual Institutional Investors Conference
Globe Newswire (Fri, 1-Mar 5:15 PM ET)
ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance
Globe Newswire (Tue, 27-Feb 4:05 PM ET)
ICU Medical Announces Time of Fourth Quarter 2023 Earnings Conference Call
Globe Newswire (Tue, 13-Feb 8:30 AM ET)
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Icu Medical trades on the NASDAQ stock market under the symbol ICUI.
As of April 25, 2024, ICUI stock price declined to $94.53 with 143,615 million shares trading.
ICUI has a beta of 1.51, meaning it tends to be more sensitive to market movements. ICUI has a correlation of 0.15 to the broad based SPY ETF.
ICUI has a market cap of $2.28 billion. This is considered a Mid Cap stock.
Last quarter Icu Medical reported $588 million in Revenue and $1.57 earnings per share. This beat revenue expectation by $25 million and exceeded earnings estimates by $.38.
In the last 3 years, ICUI stock traded as high as $282.00 and as low as $78.28.
The top ETF exchange traded funds that ICUI belongs to (by Net Assets): IJR, VTI, VB, VBR, VXF.
ICUI has underperformed the market in the last year with a price return of -48.4% while the SPY ETF gained +23.6%. ICUI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.5% and -5.3%, respectively, while the SPY returned +4.1% and -2.1%, respectively.
ICUI support price is $94.32 and resistance is $99.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICUI stock will trade within this expected range on the day.